Total testosterone and DHEAS levels as predictors of androgen-secreting neoplasms

A populational study

W. Waggoner, L. R. Boots, Ricardo Azziz

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Androgen excess affects between 2 and 10 of women. While the majority of these patients suffer from polycystic ovary syndrome, a few present with an androgen-secreting neoplasm. An elevated circulating total testosterone level and dehydroepiandiosterone sulfate (DHEAS) level have been proposed as screening methods for detecting ovarian and adrenal androgen-secreting neoplasms, respectively. To determine the predictive value of these tests for hyperandrogenic patients, we studied 478 consecutive untreated hyperandrogenic patients presenting over a ten-year period (1987-97). All had at least two of the following features: (1) oligomenorrhea (i.e. cycles > 35 days or < 8 cycles/year), (2) hyperandrogenemia (i.e. a total or free testosterone, or DHEAS > 95th percentile of controls), or (3) hirsutism (i.e. a modified Ferriman-Gallwey score ≥ 6). None of these patients had a prior diagnosis of an androgen-secreting neoplasm. Basal levels of testosterone and DHEAS were determined in all patients, with transvaginal sonography and an adrenal computed tomography scan in select individuals. Of the 478 patients included, 65 had hirsutism and oligomenorrhea; 20 had hyperandrogenic oligomenorrhea; and 15 had hirsutism and hyperandrogenemia, without overt oligomenorrhea. Overall, 11 (2.3) patients had a total testosterone > 8.7 nmol/l (250 ng/dl), of which one actually had an androgen-secreting neoplasm (i.e. true-positive). This postmenopausal patient presented with rapidly progressive virilization, and demonstrated an ovarian hilar cell tumor at surgery. The calculated sensitivity of an elevated testosterone level (> 8.67 nmol/l) for a neoplasm was 100 (1/1), the specificity was 98 (467/477), and the negative predictive value was 100 (467/467), but the positive predictive value was only 9 (1/11). Ten subjects had DHEAS levels > 16.3 μmol/l (6000 ng/ml), and none was diagnosed with an adrenocortical tumor. Although the sensitivity and positive predictive value of a high DHEAS for a neoplasm could not be calculated due to the absence of a test case, the specificity was 98 (468/478) and the negative predictive value was 100 (468/468). These data suggest that the measurement of testosterone and DHEAS is not a cost-effective method of screening for these tumors, due to the low frequency of the disorder and the fact that clinical evaluation alone is often sufficient screening.

Original languageEnglish (US)
Pages (from-to)394-400
Number of pages7
JournalGynecological Endocrinology
Volume13
Issue number6
DOIs
StatePublished - Jan 1 1999

Fingerprint

Androgens
Testosterone
Oligomenorrhea
Hirsutism
Neoplasms
Sulfates
Predictive Value of Tests
Virilism
Polycystic Ovary Syndrome
Ultrasonography
Tomography
Costs and Cost Analysis

Keywords

  • Androgen-secreting tumors
  • Androgens
  • Hirsutism
  • Screening
  • Testosterone

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Obstetrics and Gynecology

Cite this

Total testosterone and DHEAS levels as predictors of androgen-secreting neoplasms : A populational study. / Waggoner, W.; Boots, L. R.; Azziz, Ricardo.

In: Gynecological Endocrinology, Vol. 13, No. 6, 01.01.1999, p. 394-400.

Research output: Contribution to journalArticle

Waggoner, W. ; Boots, L. R. ; Azziz, Ricardo. / Total testosterone and DHEAS levels as predictors of androgen-secreting neoplasms : A populational study. In: Gynecological Endocrinology. 1999 ; Vol. 13, No. 6. pp. 394-400.
@article{3e6bcc10c8094ab995d92cbdb60ec076,
title = "Total testosterone and DHEAS levels as predictors of androgen-secreting neoplasms: A populational study",
abstract = "Androgen excess affects between 2 and 10 of women. While the majority of these patients suffer from polycystic ovary syndrome, a few present with an androgen-secreting neoplasm. An elevated circulating total testosterone level and dehydroepiandiosterone sulfate (DHEAS) level have been proposed as screening methods for detecting ovarian and adrenal androgen-secreting neoplasms, respectively. To determine the predictive value of these tests for hyperandrogenic patients, we studied 478 consecutive untreated hyperandrogenic patients presenting over a ten-year period (1987-97). All had at least two of the following features: (1) oligomenorrhea (i.e. cycles > 35 days or < 8 cycles/year), (2) hyperandrogenemia (i.e. a total or free testosterone, or DHEAS > 95th percentile of controls), or (3) hirsutism (i.e. a modified Ferriman-Gallwey score ≥ 6). None of these patients had a prior diagnosis of an androgen-secreting neoplasm. Basal levels of testosterone and DHEAS were determined in all patients, with transvaginal sonography and an adrenal computed tomography scan in select individuals. Of the 478 patients included, 65 had hirsutism and oligomenorrhea; 20 had hyperandrogenic oligomenorrhea; and 15 had hirsutism and hyperandrogenemia, without overt oligomenorrhea. Overall, 11 (2.3) patients had a total testosterone > 8.7 nmol/l (250 ng/dl), of which one actually had an androgen-secreting neoplasm (i.e. true-positive). This postmenopausal patient presented with rapidly progressive virilization, and demonstrated an ovarian hilar cell tumor at surgery. The calculated sensitivity of an elevated testosterone level (> 8.67 nmol/l) for a neoplasm was 100 (1/1), the specificity was 98 (467/477), and the negative predictive value was 100 (467/467), but the positive predictive value was only 9 (1/11). Ten subjects had DHEAS levels > 16.3 μmol/l (6000 ng/ml), and none was diagnosed with an adrenocortical tumor. Although the sensitivity and positive predictive value of a high DHEAS for a neoplasm could not be calculated due to the absence of a test case, the specificity was 98 (468/478) and the negative predictive value was 100 (468/468). These data suggest that the measurement of testosterone and DHEAS is not a cost-effective method of screening for these tumors, due to the low frequency of the disorder and the fact that clinical evaluation alone is often sufficient screening.",
keywords = "Androgen-secreting tumors, Androgens, Hirsutism, Screening, Testosterone",
author = "W. Waggoner and Boots, {L. R.} and Ricardo Azziz",
year = "1999",
month = "1",
day = "1",
doi = "10.3109/09513599909167586",
language = "English (US)",
volume = "13",
pages = "394--400",
journal = "Gynecological Endocrinology",
issn = "0951-3590",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Total testosterone and DHEAS levels as predictors of androgen-secreting neoplasms

T2 - A populational study

AU - Waggoner, W.

AU - Boots, L. R.

AU - Azziz, Ricardo

PY - 1999/1/1

Y1 - 1999/1/1

N2 - Androgen excess affects between 2 and 10 of women. While the majority of these patients suffer from polycystic ovary syndrome, a few present with an androgen-secreting neoplasm. An elevated circulating total testosterone level and dehydroepiandiosterone sulfate (DHEAS) level have been proposed as screening methods for detecting ovarian and adrenal androgen-secreting neoplasms, respectively. To determine the predictive value of these tests for hyperandrogenic patients, we studied 478 consecutive untreated hyperandrogenic patients presenting over a ten-year period (1987-97). All had at least two of the following features: (1) oligomenorrhea (i.e. cycles > 35 days or < 8 cycles/year), (2) hyperandrogenemia (i.e. a total or free testosterone, or DHEAS > 95th percentile of controls), or (3) hirsutism (i.e. a modified Ferriman-Gallwey score ≥ 6). None of these patients had a prior diagnosis of an androgen-secreting neoplasm. Basal levels of testosterone and DHEAS were determined in all patients, with transvaginal sonography and an adrenal computed tomography scan in select individuals. Of the 478 patients included, 65 had hirsutism and oligomenorrhea; 20 had hyperandrogenic oligomenorrhea; and 15 had hirsutism and hyperandrogenemia, without overt oligomenorrhea. Overall, 11 (2.3) patients had a total testosterone > 8.7 nmol/l (250 ng/dl), of which one actually had an androgen-secreting neoplasm (i.e. true-positive). This postmenopausal patient presented with rapidly progressive virilization, and demonstrated an ovarian hilar cell tumor at surgery. The calculated sensitivity of an elevated testosterone level (> 8.67 nmol/l) for a neoplasm was 100 (1/1), the specificity was 98 (467/477), and the negative predictive value was 100 (467/467), but the positive predictive value was only 9 (1/11). Ten subjects had DHEAS levels > 16.3 μmol/l (6000 ng/ml), and none was diagnosed with an adrenocortical tumor. Although the sensitivity and positive predictive value of a high DHEAS for a neoplasm could not be calculated due to the absence of a test case, the specificity was 98 (468/478) and the negative predictive value was 100 (468/468). These data suggest that the measurement of testosterone and DHEAS is not a cost-effective method of screening for these tumors, due to the low frequency of the disorder and the fact that clinical evaluation alone is often sufficient screening.

AB - Androgen excess affects between 2 and 10 of women. While the majority of these patients suffer from polycystic ovary syndrome, a few present with an androgen-secreting neoplasm. An elevated circulating total testosterone level and dehydroepiandiosterone sulfate (DHEAS) level have been proposed as screening methods for detecting ovarian and adrenal androgen-secreting neoplasms, respectively. To determine the predictive value of these tests for hyperandrogenic patients, we studied 478 consecutive untreated hyperandrogenic patients presenting over a ten-year period (1987-97). All had at least two of the following features: (1) oligomenorrhea (i.e. cycles > 35 days or < 8 cycles/year), (2) hyperandrogenemia (i.e. a total or free testosterone, or DHEAS > 95th percentile of controls), or (3) hirsutism (i.e. a modified Ferriman-Gallwey score ≥ 6). None of these patients had a prior diagnosis of an androgen-secreting neoplasm. Basal levels of testosterone and DHEAS were determined in all patients, with transvaginal sonography and an adrenal computed tomography scan in select individuals. Of the 478 patients included, 65 had hirsutism and oligomenorrhea; 20 had hyperandrogenic oligomenorrhea; and 15 had hirsutism and hyperandrogenemia, without overt oligomenorrhea. Overall, 11 (2.3) patients had a total testosterone > 8.7 nmol/l (250 ng/dl), of which one actually had an androgen-secreting neoplasm (i.e. true-positive). This postmenopausal patient presented with rapidly progressive virilization, and demonstrated an ovarian hilar cell tumor at surgery. The calculated sensitivity of an elevated testosterone level (> 8.67 nmol/l) for a neoplasm was 100 (1/1), the specificity was 98 (467/477), and the negative predictive value was 100 (467/467), but the positive predictive value was only 9 (1/11). Ten subjects had DHEAS levels > 16.3 μmol/l (6000 ng/ml), and none was diagnosed with an adrenocortical tumor. Although the sensitivity and positive predictive value of a high DHEAS for a neoplasm could not be calculated due to the absence of a test case, the specificity was 98 (468/478) and the negative predictive value was 100 (468/468). These data suggest that the measurement of testosterone and DHEAS is not a cost-effective method of screening for these tumors, due to the low frequency of the disorder and the fact that clinical evaluation alone is often sufficient screening.

KW - Androgen-secreting tumors

KW - Androgens

KW - Hirsutism

KW - Screening

KW - Testosterone

UR - http://www.scopus.com/inward/record.url?scp=0002077520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0002077520&partnerID=8YFLogxK

U2 - 10.3109/09513599909167586

DO - 10.3109/09513599909167586

M3 - Article

VL - 13

SP - 394

EP - 400

JO - Gynecological Endocrinology

JF - Gynecological Endocrinology

SN - 0951-3590

IS - 6

ER -